Integromics

Integromics was a Spanish bioinformatics company founded in 2002 as a spin-off of Spain's National Center for Biotechnology, part of the Spanish National Research Council, and the University of Malaga. Headquartered in Granada and Madrid, it developed specialist software for the management, integration, visualization, and analysis of large biological datasets. Its work addressed the growing computational needs created by microarray experiments, gene-expression studies, next-generation sequencing, proteomics, and quantitative PCR. The company emerged from an academic and research environment in which scientists needed more practical computational methods for interpreting increasingly complex experimental results. Its principal founder, Dr. José María Carazo, identified a commercial opportunity in translating advanced analytical methods into software usable by research laboratories, pharmaceutical companies, biotechnology businesses, clinical research organizations, and academic institutions. Integromics initially concentrated on microarray data analysis and subsequently expanded into a broader multi-omics portfolio. Its products included Integromics Biomarker Discovery for guided analysis of microarray gene-expression data; RealTime StatMiner for step-by-step analysis of RT-qPCR experiments; SeqSolve for tertiary analysis of next-generation sequencing data; OmicsHub Proteomics for centralized management and analysis of mass-spectrometry data; and the OmicsOffice platform, which provided a common environment for combining results from different genomics technologies. The company's software was designed to support both individual analytical workflows and larger laboratory or institutional data-management requirements. Integromics pursued partnerships to extend the reach and interoperability of its products. Its collaborations included Applied Biosystems, TIBCO Spotfire, Ingenuity, TATAA Biocenter, FPGMX, the Celgene Institute for Translational Research Europe, CEIT, and European high-performance-computing specialists. These relationships connected its software with laboratory instruments, visualization systems, pathway-analysis tools, quantitative PCR workflows, clinical-genomics initiatives, and high-performance computing infrastructure. In 2012, TIBCO Spotfire certified Integromics as its sole partner in genomics, proteomics, and bioinformatics, while in 2013 PerkinElmer received exclusive worldwide distribution rights for the OmicsOffice genomics software. The company also participated in collaborative research initiatives involving biomarker discovery, proteomics standards, lipidomics, RNA-interference screening, chronic inflammation, and healthy ageing. Its software was used in research published in journals including Nature, Cell, and Molecular & Cellular Proteomics. Recognition during its independent period included the 2007 Frost & Sullivan Product Innovation of the Year Award, the 2007 Emprendedor XXI Innovation Award, a 2010 Sello Innovación distinction, a 2011 award for the trajectory of a technology-based innovative enterprise, and recognition from Tech Media Europe and ICT Finance Marketplace in 2012. Integromics was acquired by PerkinElmer in 2017. Following the acquisition, Integromics ceased to operate as an independent company or standalone brand in the form described by its earlier corporate history. Its significance lies in its role as a Spanish research-technology spin-off that commercialized specialized computational tools for modern genomics and proteomics workflows.

Integromics originated in Spain's academic and public-research ecosystem. It was founded in 2002 as a spin-off of the National Center for Biotechnology, operated within the Spanish National Research Council, and the University of Malaga. Its principal founder, Dr. José María Carazo, saw that genomics researchers needed computational methods capable of turning increasingly large experimental datasets into usable biological findings. The company's first commercial focus was microarray data analysis, an area central to gene-expression research at the time. From its base in Granada and Madrid, Integromics developed a portfolio spanning gene expression, sequencing, proteomics, and quantitative PCR. Its software sought to guide researchers through analytical workflows rather than merely store raw data. Integromics Biomarker Discovery supported stepwise analysis of microarray gene-expression data. RealTime StatMiner addressed RT-qPCR analysis and was developed with Applied Biosystems, with compatibility for TIBCO Spotfire. SeqSolve addressed tertiary analysis of next-generation sequencing data. OmicsHub Proteomics provided centralized management and analysis capabilities for mass-spectrometry laboratories and core facilities. The OmicsOffice platform later offered a common environment for analyzing and comparing results generated by different genomics technologies. The company expanded internationally through subsidiaries in the United States and United Kingdom and distributors in additional countries. Its partnership strategy was important to this expansion. Integromics worked with Applied Biosystems, TIBCO Spotfire, Ingenuity, TATAA Biocenter, FPGMX, pharmaceutical and biotechnology organizations, and academic research institutions. In 2007 it opened a US office at the Philadelphia Science Center. In 2008 it partnered with TIBCO Spotfire on Biomarker Discovery, and in 2009 it worked with Ingenuity on integration for comprehensive genomics analysis. Its first proteomics product was released in 2009, followed by its first next-generation sequencing analysis product in 2010. Integromics' tools were associated with published research in Nature, Cell, and Molecular & Cellular Proteomics. The company also participated in collaborative projects addressing high-throughput plasma biomarker research, proteomics standards, lipidomics, RNA-interference screening, chronic inflammation, and healthy ageing. These activities positioned it between commercial software development and research infrastructure, with customers including genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. The company received several innovation and technology-enterprise distinctions. In 2007 it received the Frost & Sullivan Product Innovation of the Year Award and the Emprendedor XXI Innovation Award. It later received recognition connected with the Sello Innovación program, the trajectory of technology-based innovative enterprises, and Tech Media Europe and ICT Finance Marketplace. In 2012, TIBCO Spotfire certified Integromics as its sole partner in genomics, proteomics, and bioinformatics. In 2013, PerkinElmer became the exclusive worldwide distributor of new OmicsOffice genomics software, deepening a commercial relationship that preceded the eventual acquisition. PerkinElmer acquired Integromics in 2017. The acquisition brought the Spanish bioinformatics company's technology and capabilities into PerkinElmer's broader life-science business. Integromics is therefore best treated as a defunct independent company whose historical identity is tied to software for multi-omics data analysis and to the commercialization of research tools developed from Spanish academic expertise.

• 2017

  Acquisition by PerkinElmer

  [1]Integromicsen.wikipedia.org

  PerkinElmer acquires Integromics, ending its operation as an independent company.

• 2013

  PerkinElmer becomes exclusive worldwide distributor

  [1]Integromicsen.wikipedia.org

  PerkinElmer receives exclusive worldwide distribution rights for Integromics' OmicsOffice genomics software.

• 2012

  OmicsOffice platform launches

  [1]Integromicsen.wikipedia.org

  Integromics introduces a platform intended to provide a common environment for combining results from different genomics technologies.

• 2011

  OmicsHub Proteomics 2.0 launches

  [1]Integromicsen.wikipedia.org

  The updated OmicsHub platform targets centralized data management and analysis in mass-spectrometry laboratories and core facilities.

• 2010

  Entry into next-generation sequencing analysis

  [1]Integromicsen.wikipedia.org

  The company releases its first next-generation sequencing analysis product and collaborates with TATAA Biocenter on quantitative PCR analysis.

• 2009

  Expansion into proteomics

  [1]Integromicsen.wikipedia.org

  Integromics releases its first proteomics product and receives venture investment from I+D Unifondo.

• 2007

  International expansion and industry partnerships

  [1]Integromicsen.wikipedia.org

  The company partners with Applied Biosystems, opens a United States office at the Philadelphia Science Center, and receives two innovation-related awards.

• 2002

  Integromics is founded as a research spin-off

  [1]Integromicsen.wikipedia.org

  Integromics is established as a spin-off of the National Center for Biotechnology and the University of Malaga, with José María Carazo as principal founder.

A research-oriented bioinformatics software company focused on making complex genomics, proteomics, sequencing, gene-expression, and quantitative PCR datasets easier to manage, integrate, and interpret.

• Next-generation sequencing analysis software · 2010

  SeqSolve

  SeqSolve was Integromics' software for tertiary analysis of next-generation sequencing data. It supported interpretation of sequencing results after primary instrument processing and was associated with research publications involving RNA and genome-wide profiling. The product represented the company's move from earlier microarray-focused analysis into newer sequencing workflows.

• RT-qPCR data-analysis software

  RealTime StatMiner

  RealTime StatMiner provided a guided workflow for analyzing real-time quantitative PCR data. It was available as a standalone application and in a form compatible with TIBCO Spotfire. The product was co-developed with Applied Biosystems and was intended to help researchers move from experimental measurements to statistically interpretable results.

• Microarray and gene-expression analysis software

  Integromics Biomarker Discovery

  Integromics Biomarker Discovery was designed for analysis of microarray gene-expression data. Its guided, step-by-step workflow helped users examine expression results and identify candidate biological patterns or biomarkers. The product was developed in connection with TIBCO Spotfire and formed part of Integromics' early emphasis on making complex genomics analysis more accessible to research teams.

• Proteomics data-management and analysis platform · 2009

  OmicsHub Proteomics

  OmicsHub Proteomics was a platform for centralized management and analysis of proteomics data, particularly in mass-spectrometry laboratories and shared core facilities. It addressed the organizational and analytical challenges created when multiple experiments, instruments, and researchers contribute data to the same laboratory environment.

• Multi-omics analysis platform · 2012

  OmicsOffice

  OmicsOffice was positioned as a shared analytical environment for working with results from multiple genomics technologies. It aimed to streamline analysis and allow researchers to compare and combine outputs across experimental methods. PerkinElmer became its exclusive worldwide distributor in 2013 before acquiring Integromics in 2017.

• 2017

  Acquisition by PerkinElmerM&A

  Background

  Integromics had developed a specialized portfolio of software for genomics, proteomics, sequencing, and related analytical workflows.

  Action taken

  PerkinElmer acquired Integromics.

  Aftermath

  Integromics ceased to operate as an independent company, and its historical standalone brand identity ended.

  Source

• 2013

  Exclusive worldwide distribution agreement with PerkinElmerStrategy

  Background

  Integromics sought broader international distribution for its OmicsOffice genomics software.

  Action taken

  The company granted PerkinElmer exclusive worldwide distribution rights for the new OmicsOffice genomics software.

  Aftermath

  The commercial relationship preceded PerkinElmer's acquisition of Integromics in 2017.

  Source

• 2012

  Launch of the OmicsOffice platformProduct launch

  Background

  Researchers were increasingly combining results from different genomics technologies, creating a need for a more unified analysis environment.

  Action taken

  Integromics introduced OmicsOffice as a platform for analyzing, comparing, and combining results from multiple genomics workflows.

  Aftermath

  The platform became the subject of an exclusive worldwide distribution agreement with PerkinElmer in 2013.

  Source

1. 1Integromicsen.wikipedia.org